X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hypocalcemia - chemically induced (992) 992
humans (897) 897
male (628) 628
female (622) 622
animals (434) 434
calcium - blood (333) 333
middle aged (279) 279
adult (275) 275
aged (239) 239
hypocalcemia (225) 225
rats (201) 201
index medicus (192) 192
magnesium - blood (121) 121
phosphates - blood (121) 121
calcium - metabolism (117) 117
hypocalcemia - blood (110) 110
hypocalcemia - drug therapy (109) 109
calcium (105) 105
time factors (103) 103
endocrinology & metabolism (93) 93
medicine, general & internal (87) 87
hypocalcemia - complications (86) 86
calcitonin - pharmacology (84) 84
adolescent (83) 83
diphosphonates - adverse effects (83) 83
parathyroid hormone - blood (83) 83
child (79) 79
bone density conservation agents - adverse effects (73) 73
hypocalcemia - etiology (72) 72
hypercalcemia - chemically induced (69) 69
aged, 80 and over (67) 67
pregnancy (66) 66
urology & nephrology (63) 63
hypocalcemia - physiopathology (60) 60
phosphates - adverse effects (60) 60
cattle (58) 58
pharmacology & pharmacy (58) 58
treatment outcome (56) 56
risk factors (54) 54
antineoplastic agents - adverse effects (53) 53
child, preschool (52) 52
hypokalemia - chemically induced (52) 52
oncology (52) 52
pediatrics (52) 52
infusions, intravenous (51) 51
tetany - chemically induced (51) 51
phosphorus - blood (50) 50
hypocalcemia - veterinary (49) 49
calcium - therapeutic use (48) 48
infant (48) 48
magnesium deficiency - chemically induced (47) 47
vitamin d (47) 47
bone neoplasms - secondary (46) 46
dogs (46) 46
hypocalcemia - diagnosis (46) 46
anticonvulsants - adverse effects (45) 45
diphosphonates - therapeutic use (44) 44
infant, newborn (44) 44
retrospective studies (44) 44
thyroidectomy (44) 44
dose-response relationship, drug (43) 43
therapy (42) 42
swine (41) 41
calcitonin (40) 40
hypocalcemia - metabolism (40) 40
bone neoplasms - drug therapy (39) 39
denosumab (39) 39
imidazoles - adverse effects (39) 39
osteoporosis (39) 39
parathyroid hormone (39) 39
administration, oral (38) 38
calcium - urine (37) 37
hypocalcaemia (37) 37
bone density conservation agents - therapeutic use (36) 36
bone resorption - drug effects (36) 36
hyperphosphatemia (36) 36
injections, intravenous (36) 36
rabbits (36) 36
zoledronic acid (36) 36
edetic acid (35) 35
magnesium (34) 34
epilepsy - drug therapy (33) 33
medicine & public health (33) 33
phosphates - administration & dosage (33) 33
alkaline phosphatase - blood (32) 32
cancer (32) 32
care and treatment (32) 32
hypomagnesemia (32) 32
mice (32) 32
biological assay (31) 31
vitamin d - therapeutic use (31) 31
hypercalcemia - drug therapy (30) 30
diphosphonates - administration & dosage (29) 29
electrocardiography (29) 29
hypocalcemia - prevention & control (29) 29
hypoparathyroidism (29) 29
parathyroid glands - physiology (29) 29
proton pump inhibitors - adverse effects (29) 29
severity of illness index (29) 29
veterinary sciences (29) 29
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1089) 1089
French (45) 45
German (31) 31
Spanish (20) 20
Russian (14) 14
Polish (10) 10
Italian (8) 8
Japanese (7) 7
Dutch (6) 6
Danish (4) 4
Norwegian (4) 4
Czech (3) 3
Hungarian (2) 2
Arabic (1) 1
Chinese (1) 1
Croatian (1) 1
Hebrew (1) 1
Portuguese (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Critical Care Medicine, ISSN 0090-3493, 06/2010, Volume 38 Suppl, Identification and Prevention of Common Adverse Drug Events in the Intensive Care Unit, Issue 6, pp. S253 - S264
Electrolyte imbalances are common in critically ill patients. Although multiple disease states typically encountered in the intensive care unit may be... 
Hypercalcemia | Critical illness | Hyperkalemia | Hyponatremia | Hypernatremia | Hypermagnesemia | Hyperphosphatemia | Hypokalemia | Hypophosphatemia | Water-electrolyte imbalance | Hypocalcemia | Hypomagnesemia | HOSPITALIZED-PATIENTS | hypernatremia | critical illness | hyperkalemia | AMPHOTERICIN-B NEPHROTOXICITY | DRUG-INDUCED HYPERKALEMIA | CONVERTING ENZYME-INHIBITORS | hypercalcemia | CATION-EXCHANGE RESIN | hypokalemia | hypocalcemia | hyperphosphatemia | hyponatremia | HEPARIN-INDUCED HYPERKALEMIA | TRIMETHOPRIM-SULFAMETHOXAZOLE THERAPY | hypomagnesemia | hypermagnesemia | RENAL TUBULAR-ACIDOSIS | NEPHROGENIC DIABETES-INSIPIDUS | hypophosphatemia | CRITICALLY-ILL PATIENTS | water-electrolyte imbalance | CRITICAL CARE MEDICINE | Critical Care - methods | Hypernatremia - physiopathology | Hyponatremia - chemically induced | Hypocalcemia - physiopathology | Magnesium Deficiency - physiopathology | United States | Humans | Hypocalcemia - chemically induced | Magnesium Deficiency - chemically induced | Hypokalemia - chemically induced | Hyponatremia - physiopathology | Hypophosphatemia - chemically induced | Hypokalemia - physiopathology | Intensive Care Units | Hyperphosphatemia - chemically induced | Water-Electrolyte Imbalance - chemically induced | Hyperkalemia - physiopathology | Drug-Related Side Effects and Adverse Reactions - etiology | Magnesium - metabolism | Hypercalcemia - chemically induced | Hypernatremia - chemically induced | Hypercalcemia - physiopathology | Hypophosphatemia - physiopathology | Water-Electrolyte Imbalance - physiopathology | Hyperkalemia - chemically induced | Hyperphosphatemia - physiopathology | Drug-Related Side Effects and Adverse Reactions - physiopathology | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
American Journal of Kidney Diseases, ISSN 0272-6386, 2010, Volume 56, Issue 1, pp. 112 - 116
Journal Article
American Journal of Kidney Diseases, ISSN 0272-6386, 11/2017, Volume 70, Issue 5, pp. 725 - 728
Journal Article
Endocrine-related Cancer, ISSN 1351-0088, 2015, Volume 22, Issue 6, pp. 877 - 887
Effective adverse event (AE) management is critical to maintaining patients on anticancer therapies. The DECISION trial was a multicenter, randomized,... 
Adverse events | Targeted therapy | Tyrosine kinase inhibitor | Sorafenib | Differentiated thyroid cancer | targeted therapy | sorafenib | EFFICACY | GUIDELINES | TIME | adverse events | differentiated thyroid cancer | DECREASES | TRIAL | ONCOLOGY | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | tyrosine kinase inhibitor | RENAL-CELL | EXPOSURE | Adenoma, Oxyphilic - enzymology | Dyspnea - chemically induced | Thyroid Neoplasms - enzymology | Prevalence | Adenocarcinoma, Follicular - radiotherapy | Humans | Middle Aged | Drug Resistance, Neoplasm | Hypertension - drug therapy | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Protein Kinase Inhibitors - adverse effects | Weight Loss - drug effects | Incidence | Neoplasms, Second Primary - chemically induced | Adenocarcinoma, Follicular - drug therapy | Adenoma, Oxyphilic - drug therapy | Hypocalcemia - epidemiology | Niacinamide - adverse effects | Carcinoma, Papillary - drug therapy | Niacinamide - therapeutic use | Thyroid Neoplasms - radiotherapy | Adenocarcinoma, Follicular - enzymology | Neoplasms, Second Primary - epidemiology | Niacinamide - analogs & derivatives | Diarrhea - epidemiology | Diarrhea - chemically induced | Iodine Radioisotopes - therapeutic use | Hypocalcemia - chemically induced | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Female | Carcinoma, Papillary - enzymology | Hypertension - epidemiology | Adenoma, Oxyphilic - radiotherapy | Drug Eruptions - etiology | Phenylurea Compounds - therapeutic use | Dyspnea - epidemiology | Disease-Free Survival | Carcinoma, Papillary - radiotherapy | Fatigue - epidemiology | Thyroid Neoplasms - drug therapy | Protein Kinase Inhibitors - therapeutic use | Aged | Diarrhea - drug therapy | Drug Eruptions - epidemiology | Radiopharmaceuticals - therapeutic use | Index Medicus | Research
Journal Article
Critical Care, ISSN 1364-8535, 09/2015, Volume 19, Issue 1, p. 349
Journal Article
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 05/2016, Volume 72, Issue 5, pp. 641 - 643
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00228-016-2024-2 
Neurotoxicity Syndromes - etiology | Proton Pump Inhibitors - adverse effects | Hypocalcemia - chemically induced | Humans | Hypokalemia - chemically induced | Aged, 80 and over | Female | Magnesium - metabolism | Male | Metabolic Diseases - chemically induced | Aged | Proton pump inhibitors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2012, Volume 367, Issue 26, pp. 2482 - 2494
Journal Article